Loading
NASDAQHealthcareBiotechnology
Latest quote
$0.4675
+$0.0266 · +6.03%
Pasithea Therapeutics Corp. functions as a biotechnology firm dedicated to the discovery and advancement of novel therapeutic solutions for various psychiatric and neurological conditions. Beyond its research endeavors, the company also plans to establish and manage clinics specializing in depression treatment. These facilities are designed to offer business support, employing trained pharmacists to administer intravenous ketamine infusions. Founded in 2020, the corporation's primary operations are based in Miami Beach, Florida.
Previous close
$0.4675
+$0.0266 · +6.03%
After-hours
$0.4633
−$0.0042 · -0.90%
Oct 9, 7:55 PM ET
Regular session · ET · Market data may be delayed.
Pasithea Therapeutics Corp. functions as a biotechnology firm dedicated to the discovery and advancement of novel therapeutic solutions for various psychiatric and neurological conditions. Beyond its research endeavors, the company also plans to establish and manage clinics specializing in depression treatment. These facilities are designed to offer business support, employing trained pharmacists to administer intravenous ketamine infusions. Founded in 2020, the corporation's primary operations are based in Miami Beach, Florida.
Day range
Current $0.4675
52-week range
Current $0.4675
Regular session · ET · Market data may be delayed.
GoAI Score
Sell
Valuation
55
Fair Value
Sentiment
58
Mixed
Risk
66
High Risk
Momentum
18
Strong Down
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Pasithea Therapeutics Corp. functions as a biotechnology firm dedicated to the discovery and advancement of novel therapeutic solutions for various psychiatric and neurological conditions. Beyond its research endeavors, the company also plans to establish and manage clinics specializing in depression treatment. These facilities are designed to offer business support, employing trained pharmacists to administer intravenous ketamine infusions. Founded in 2020, the corporation's primary operations are based in Miami Beach, Florida.
Day range
Current $0.4675
52-week range
Current $0.4675
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | — | — | — | — | 15.06K USD |
| Cost of goods sold | — | — | — | 5.09K USD | 17.28K USD |
| Gross profit | — | — | — | −5.09K USD | −2.21K USD |
| Research and development | 7.98M USD | 7.2M USD | 8.1M USD | 2.67M USD | — |
| Selling, general, and administrative | 12.88M USD | 7.05M USD | 7.88M USD | 9.92M USD | 4.51M USD |
| Operating expenses | 20.86M USD | 14.25M USD | 15.98M USD | 12.58M USD | 4.51M USD |
| Interest income | 327.19K USD | 423.18K USD | 415.37K USD | — | — |
| Interest expense | — | — | — | 102 USD | 508 USD |
| Depreciation and amortization | 662.59K USD | 649.03K USD | 648.45K USD | 5.09K USD | 1.38K USD |
| Operating income | −20.86M USD | −14.25M USD | −15.98M USD | −12.59M USD | −4.51M USD |
| Net income | −20.43M USD | −13.9M USD | −15.96M USD | −13.94M USD | −2.17M USD |
Company facts updated Oct 10, 2026.
Recent quarterly results
Recent quarterly results
Third-party consensus; not a GoAI recommendation.
Average target
$3.00
541.71% upside| Action | Effective date | Details | Record date | Payment date |
|---|---|---|---|---|
Stock split | Jan 2, 2024 | 1:20 | — | — |
Effective Jan 2, 2024
1:20
Funds reporting this stock among their holdings, ordered by reported position size.
AI-generated and delayed market data for informational and educational purposes only. Not investment advice.
